Beyond the diagnosis: What living with bladder cancer really looks like

When someone hears the words, “you have bladder cancer,” the conversation often turns immediately to understanding the disease, exploring appropriate care options, and determining how best to manage it over time.

But for many people living with bladder cancer, the experience extends far beyond clinical care. It shapes how they see themselves, how they live their daily lives, and how they navigate uncertainty about the future.

A new global survey conducted by The Harris Poll on behalf of Johnson & Johnson and in collaboration with leading professional and patient organizations—the Bladder Cancer Advocacy Network (BCAN), the International Bladder Cancer Group (IBCG), and the World Bladder Cancer Patient Coalition (WBCPC)—offers a deeper look at those experiences.

The survey included 817 people living with non–muscle invasive bladder cancer (NMIBC) and 802 urologists across six countries, revealing a central insight: many patients quietly carry the physical, mental, and emotional burdens of bladder cancer and its current standard-of-care treatments—burdens that often remain unseen in routine care conversations.

Key findings

The survey revealed several consistent themes across patient and urologist experiences:

Understanding bladder cancer

Bladder cancer is often overlooked despite being the ninth most common cancer globally, with more than 614,000 new cases diagnosed each year.

The disease generally begins in the inner lining of the bladder, the organ that stores urine before it leaves the body. Most patients receive care from a urologist, a physician who specializes in diagnosing and treating diseases of the urinary system. After diagnosis, a urologist determines how deeply the cancer has grown into the bladder wall to guide treatment decisions.

Bladder cancer can be categorized based on how far the tumor has spread into the bladder wall:

• NMIBC, which accounts for roughly 75 percent of new diagnoses, where cancer cells are found in the inner lining of the bladder, or within loose connective tissue below this inner layer, but have not grown into the muscle layer of the bladder wall
• Muscle-invasive bladder cancer, where tumors have invaded the bladder muscle with or without lymph node involvement
• Advanced and metastatic urothelial cancer (mUC), where locally advanced tumors may have spread to nearby organs and include tumors that have disseminated to distant organs such as the lungs or liver, or to bones

Although NMIBC is considered an earlier stage, it often behaves like a chronic condition. Patients typically undergo regular monitoring and repeated procedures to watch for recurrence. For many, bladder cancer does not end after initial treatment; it becomes part of long-term management.

Current standard-of-care treatments carry a patient-reported toll

For many patients surveyed, the impact of bladder cancer treatment extends far beyond the clinic and is often felt in ways that are both physical and deeply personal. More than nine in 10 patients surveyed who underwent bladder removal* or BCG** treatment reported negative physical, mental, and emotional impacts, with more than half describing these effects as moderate or significant.

For some, this means adapting to lasting changes to their body, including managing urinary diversion systems that collect urine in an external pouch following bladder removal. These adjustments can affect not only physical comfort, but also how patients see themselves and navigate daily life.

Patients treated with BCG, one of the most common therapies for NMIBC, also describe a deeply personal toll. Many reported that treatment affected their sense of dignity or sense of self. Others described a loss of control over their bodies, or the need to manage treatment-related physical symptoms as humiliating. More than three-quarters reported they did not feel like themselves during treatment.

When treatment changes daily life

Bladder cancer treatment can also affect daily routines in ways many patients do not anticipate.

For many, that impact is immediate and visible in everyday moments. In fact, patients commonly reported missing important life moments due to treatment, including more than one in three who said they avoided leaving their home, going out in public, or socializing with friends and family.

Together, these experiences underscore how bladder cancer treatment can reshape daily life in lasting ways, affecting not only health outcomes, but also how people live, connect, and see themselves.

When patients seem okay—but may not be

On the surface, communication between patients and their urologists appears strong. Nearly nine in 10 patients surveyed reported feeling comfortable having open and honest conversations with their urologist.

But the survey results reveal a more complex reality, one that is not always visible during routine care.

More than half of patients surveyed said they hide their feelings about the emotional impact of bladder cancer from their urologist, and nearly one in three said they often or always conceal how they feel. At the same time, 86 percent of patients reported constantly worrying about their cancer coming back or getting worse.

Meanwhile, most urologists surveyed believe their patients are comfortable discussing emotional concerns. This disconnect highlights a subtle but important blind spot in care. Patients may deeply trust their urologists and rely on them for treatment decisions, but that trust does not always translate into conversations about mental and emotional wellbeing. Clinic visits often focus on physical symptoms, test results, and treatment plans, while the emotional toll remains largely unspoken.

Many urologists recognize this challenge. In fact, 78 percent reported they wish they could dedicate more time to discussing the mental and emotional impact of bladder cancer during appointments.

Strong alignment around continued progress

Despite these challenges, the survey also reveals something encouraging. Patients and urologists are aligned in their interest in progress, with a strong majority expressing interest in more innovative treatment approaches beyond those commonly used today.

In addition, 90 percent of urologists surveyed said they wish there were better ways to address the emotional and mental impacts of bladder cancer treatment.

Together, these findings suggest a shared interest in continuing to evolve bladder cancer care in ways that better reflect the lived experience of patients.

Treating the whole person, not just the tumor

The findings from this global survey highlight an important truth: while medical advances focus on treating the disease, the experience of living with bladder cancer extends far beyond the tumor itself.

Behind every diagnosis is a person navigating fear, uncertainty, resilience, and hope. Making space for those experiences, and for open conversations about them, can help strengthen partnerships between patients and healthcare providers.

As awareness grows, so does the opportunity to ensure bladder cancer care reflects not only the disease being treated, but the lives of those living with it.

Methodology

The research was conducted online within the United States, Brazil, France, Germany, Japan, and Mexico by The Harris Poll on behalf of Johnson & Johnson among 817 NMIBC patients (i.e., adults aged 18 or older who have been diagnosed by an HCP with bladder cancer, have specifically been diagnosed with NMIBC, and have a urologist who is primarily responsible for treating their bladder cancer) and 802 urologists who see/treat NMIBC patients (i.e., adults aged 18 or older who are a physician specializing in urology, who see/treat at least 1 bladder cancer patient in a typical month, and who have seen/treated at least 1 NMIBC patient in the last 3 months). The survey was conducted November 25 – December 29, 2025. Individual countries are combined with a post weight to give each country an equal proportion of the total. Patients and physicians who qualified for and successfully completed the survey were compensated for their participation.

For complete survey methodology, including weighting variables and subgroup sample sizes, please contact oncology_media_relations@its.jnj.com.

*n=117
**n=486